Vaccine Market Forecasts to 2034 – Global Analysis By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, mRNA Vaccines, Viral Vector Vaccines, DNA Vaccines, and Combination Vaccines), Valency Type, Disease Indication, Route of Administration, Age Group, Manufacturing Model, Storage & Logistics, End User, Distribution Channel, and By Geography
According to Stratistics MRC, the Global Vaccine Market is accounted for $91.4 billion in 2026 and is expected to reach $155.9 billion by 2034 growing at a CAGR of 6.9% during the forecast period. Vaccines are biological preparations that provide active acquired immunity to specific infectious diseases, playing a critical role in global public health through disease prevention and eradication efforts. The market encompasses a wide range of vaccine types including pediatric, adult, influenza, COVID-19, travel, and therapeutic vaccines targeting various infectious conditions. Increasing disease outbreaks, growing geriatric populations susceptible to infections, continuous research investments, and expanding immunization programs across developing nations collectively drive the sustained expansion of this essential healthcare market.
Market Dynamics:
Driver:
Rising incidence of infectious diseases and pandemic threats
Recurring outbreaks of infectious diseases including measles, dengue, Ebola, and novel influenza strains continuously reinforce the critical importance of vaccination programs worldwide. The recent COVID-19 pandemic demonstrated both the devastating economic and health impacts of emerging pathogens and the remarkable potential of rapid vaccine development platforms. This heightened awareness has translated into sustained government funding, accelerated regulatory pathways, and unprecedented public acceptance of immunization. Emerging economies facing dual burdens of endemic and emerging infectious diseases represent particularly strong demand drivers, as healthcare infrastructure expansion increasingly prioritizes preventative medicine over reactive treatment approaches.
Restraint:
High costs of vaccine development and cold chain logistics
Developing a single new vaccine typically requires ten to fifteen years and investments exceeding one billion dollars, creating substantial barriers for smaller manufacturers and emerging market entrants. The stringent regulatory environment demands extensive clinical trials across diverse populations, further escalating development timelines and financial requirements. Additionally, the temperature-sensitive nature of most vaccines necessitates sophisticated cold chain infrastructure from manufacturing facilities to final administration points, representing significant logistical challenges in remote and resource-limited settings. These combined cost pressures limit market accessibility, particularly for vaccines targeting diseases prevalent primarily in low-income regions with limited ability to pay premium pricing.
Opportunity:
Expansion of mRNA and novel platform technologies
The remarkable success of mRNA vaccines during the COVID-19 pandemic has revolutionized vaccine development paradigms, opening unprecedented opportunities for rapid response to emerging threats and previously challenging targets. These platform technologies enable faster design and manufacturing adaptation compared to traditional approaches, substantially reducing development timelines for pandemic responses. Beyond infectious diseases, mRNA platforms are being investigated for therapeutic cancer vaccines, autoimmune conditions, and rare genetic disorders, dramatically expanding the addressable market. Multiple manufacturers are now investing heavily in platform diversification, manufacturing scale-up, and distribution capabilities, positioning these technologies as transformative forces across the broader vaccine landscape.
Threat:
Vaccine hesitancy and misinformation campaigns
Persistent public skepticism regarding vaccine safety and efficacy continues to undermine immunization coverage rates even in well-developed healthcare systems with established track records of disease prevention. Social media platforms and online communities amplify scientifically unsubstantiated claims, creating information ecosystems where misinformation spreads faster than accurate public health messaging. This hesitancy has contributed to resurgent measles outbreaks in regions previously declared elimination-free and slowed COVID-19 booster adoption despite ongoing viral evolution. Addressing these behavioral barriers requires substantial investments in community engagement, healthcare worker training, and culturally tailored communication strategies, representing non-technical challenges that traditional pharmaceutical approaches cannot alone resolve.
Covid-19 Impact:
The COVID-19 pandemic fundamentally transformed the vaccine market through unprecedented collaboration, funding acceleration, and public awareness. Regulatory bodies implemented emergency use authorizations and rolling review processes, compressing traditional multi-year approval timelines into months without compromising safety standards. Massive government investments in manufacturing capacity, including partnerships between competing pharmaceutical companies, enabled billions of doses to be produced and distributed globally. The pandemic also normalized adult vaccination as a routine public health practice in many regions, creating sustained demand for booster doses and expanded adult immunization schedules. These structural changes have permanently elevated baseline vaccine utilization and accelerated pipeline development across multiple disease targets.
The Hospitals segment is expected to be the largest during the forecast period
The Hospitals segment is expected to account for the largest market share during the forecast period, driven by their comprehensive infrastructure, trained medical personnel, and ability to handle complex vaccination scenarios including adverse reaction management. Hospitals serve as primary vaccination sites for newborns, pre-travel consultations, occupational health programs, and catch-up immunizations for previously missed doses. Their centralized role in healthcare delivery systems, particularly in managing large-scale emergency responses, makes them indispensable partners in routine and pandemic immunization efforts. The integration of vaccination records with electronic health records in hospital settings further strengthens this channel's dominance by enabling better tracking, reminder systems, and coordination across multiple vaccine types and schedules.
The Retail Pharmacies segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Retail Pharmacies segment is predicted to witness the highest growth rate, reflecting the shift toward convenient, accessible vaccination services outside traditional medical settings. Pharmacies offer extended hours, walk-in appointments, and locations embedded within communities, significantly reducing access barriers for working adults and rural populations. Expanded scope-of-practice regulations across multiple countries now authorize pharmacists to administer a growing range of vaccines, including influenza, pneumococcal, shingles, and COVID-19 boosters. The retail pharmacy model's lower overhead costs compared to hospital settings enable more competitive pricing, while established medication management systems integrate seamlessly with immunization services, creating efficient, patient-centered delivery platforms that continue gaining regulatory approval and consumer acceptance.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share, supported by advanced healthcare infrastructure, high per capita healthcare spending, and established immunization schedules across all age groups. The region's concentration of major vaccine manufacturers and research institutions drives continuous innovation and maintains robust supply chains for routine and pandemic vaccines. Strong public-private partnerships, including extensive pharmacy-based administration networks, create multiple access points ensuring high coverage rates. Government-funded programs like Vaccines for Children eliminate cost barriers for vulnerable populations, while private insurance mandates ensure comprehensive adult coverage. This mature ecosystem, combined with ongoing investments in next-generation vaccine development, reinforces North America's market leadership throughout the forecast timeline.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by large and growing populations, expanding government immunization commitments, and improving healthcare infrastructure across multiple countries. Rapid economic growth in China, India, and Southeast Asian nations has enabled increased domestic vaccine manufacturing capacity and public health investments. Significant birth cohorts create sustained demand for pediatric vaccines, while aging populations require expanded adult immunization programs against influenza, pneumococcal disease, and herpes zoster. Regional initiatives promoting indigenous vaccine production, including the Serum Institute of India's massive manufacturing scale, reduce import dependence and improve supply security. International organization partnerships supporting immunization expansion in lower-income Asia Pacific countries further accelerate regional market growth.
Key players in the market
Some of the key players in Vaccine Market include Pfizer Inc, Moderna Inc, Johnson and Johnson, GlaxoSmithKline plc, Sanofi SA, Merck and Co Inc, AstraZeneca plc, Bharat Biotech International Limited, Serum Institute of India Pvt Ltd, Sinovac Biotech Ltd, Sinopharm Group Co Ltd, CSL Limited, Novavax Inc, BioNTech SE, Takeda Pharmaceutical Company Limited, and Emergent BioSolutions Inc.
Key Developments:
In April 2026, The European Commission approved ENFLONSIA (clesrovimab) for the prevention of RSV lower respiratory tract disease in infants during their first RSV season.
In March 2026, GSK’s Respiratory Syncytial Virus (RSV) vaccine, Arexvy, received FDA approval for an expanded age indication; covering adults aged 18–49 who are at increased risk of severe infection.
In December 2025, CSL officially opened its new $1 billion world-class vaccine and antivenom manufacturing facility in Melbourne, Australia, significantly boosting onshore cell-based influenza vaccine production.
Vaccine Types Covered:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
Market Dynamics:
Driver:
Rising incidence of infectious diseases and pandemic threats
Recurring outbreaks of infectious diseases including measles, dengue, Ebola, and novel influenza strains continuously reinforce the critical importance of vaccination programs worldwide. The recent COVID-19 pandemic demonstrated both the devastating economic and health impacts of emerging pathogens and the remarkable potential of rapid vaccine development platforms. This heightened awareness has translated into sustained government funding, accelerated regulatory pathways, and unprecedented public acceptance of immunization. Emerging economies facing dual burdens of endemic and emerging infectious diseases represent particularly strong demand drivers, as healthcare infrastructure expansion increasingly prioritizes preventative medicine over reactive treatment approaches.
Restraint:
High costs of vaccine development and cold chain logistics
Developing a single new vaccine typically requires ten to fifteen years and investments exceeding one billion dollars, creating substantial barriers for smaller manufacturers and emerging market entrants. The stringent regulatory environment demands extensive clinical trials across diverse populations, further escalating development timelines and financial requirements. Additionally, the temperature-sensitive nature of most vaccines necessitates sophisticated cold chain infrastructure from manufacturing facilities to final administration points, representing significant logistical challenges in remote and resource-limited settings. These combined cost pressures limit market accessibility, particularly for vaccines targeting diseases prevalent primarily in low-income regions with limited ability to pay premium pricing.
Opportunity:
Expansion of mRNA and novel platform technologies
The remarkable success of mRNA vaccines during the COVID-19 pandemic has revolutionized vaccine development paradigms, opening unprecedented opportunities for rapid response to emerging threats and previously challenging targets. These platform technologies enable faster design and manufacturing adaptation compared to traditional approaches, substantially reducing development timelines for pandemic responses. Beyond infectious diseases, mRNA platforms are being investigated for therapeutic cancer vaccines, autoimmune conditions, and rare genetic disorders, dramatically expanding the addressable market. Multiple manufacturers are now investing heavily in platform diversification, manufacturing scale-up, and distribution capabilities, positioning these technologies as transformative forces across the broader vaccine landscape.
Threat:
Vaccine hesitancy and misinformation campaigns
Persistent public skepticism regarding vaccine safety and efficacy continues to undermine immunization coverage rates even in well-developed healthcare systems with established track records of disease prevention. Social media platforms and online communities amplify scientifically unsubstantiated claims, creating information ecosystems where misinformation spreads faster than accurate public health messaging. This hesitancy has contributed to resurgent measles outbreaks in regions previously declared elimination-free and slowed COVID-19 booster adoption despite ongoing viral evolution. Addressing these behavioral barriers requires substantial investments in community engagement, healthcare worker training, and culturally tailored communication strategies, representing non-technical challenges that traditional pharmaceutical approaches cannot alone resolve.
Covid-19 Impact:
The COVID-19 pandemic fundamentally transformed the vaccine market through unprecedented collaboration, funding acceleration, and public awareness. Regulatory bodies implemented emergency use authorizations and rolling review processes, compressing traditional multi-year approval timelines into months without compromising safety standards. Massive government investments in manufacturing capacity, including partnerships between competing pharmaceutical companies, enabled billions of doses to be produced and distributed globally. The pandemic also normalized adult vaccination as a routine public health practice in many regions, creating sustained demand for booster doses and expanded adult immunization schedules. These structural changes have permanently elevated baseline vaccine utilization and accelerated pipeline development across multiple disease targets.
The Hospitals segment is expected to be the largest during the forecast period
The Hospitals segment is expected to account for the largest market share during the forecast period, driven by their comprehensive infrastructure, trained medical personnel, and ability to handle complex vaccination scenarios including adverse reaction management. Hospitals serve as primary vaccination sites for newborns, pre-travel consultations, occupational health programs, and catch-up immunizations for previously missed doses. Their centralized role in healthcare delivery systems, particularly in managing large-scale emergency responses, makes them indispensable partners in routine and pandemic immunization efforts. The integration of vaccination records with electronic health records in hospital settings further strengthens this channel's dominance by enabling better tracking, reminder systems, and coordination across multiple vaccine types and schedules.
The Retail Pharmacies segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Retail Pharmacies segment is predicted to witness the highest growth rate, reflecting the shift toward convenient, accessible vaccination services outside traditional medical settings. Pharmacies offer extended hours, walk-in appointments, and locations embedded within communities, significantly reducing access barriers for working adults and rural populations. Expanded scope-of-practice regulations across multiple countries now authorize pharmacists to administer a growing range of vaccines, including influenza, pneumococcal, shingles, and COVID-19 boosters. The retail pharmacy model's lower overhead costs compared to hospital settings enable more competitive pricing, while established medication management systems integrate seamlessly with immunization services, creating efficient, patient-centered delivery platforms that continue gaining regulatory approval and consumer acceptance.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share, supported by advanced healthcare infrastructure, high per capita healthcare spending, and established immunization schedules across all age groups. The region's concentration of major vaccine manufacturers and research institutions drives continuous innovation and maintains robust supply chains for routine and pandemic vaccines. Strong public-private partnerships, including extensive pharmacy-based administration networks, create multiple access points ensuring high coverage rates. Government-funded programs like Vaccines for Children eliminate cost barriers for vulnerable populations, while private insurance mandates ensure comprehensive adult coverage. This mature ecosystem, combined with ongoing investments in next-generation vaccine development, reinforces North America's market leadership throughout the forecast timeline.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by large and growing populations, expanding government immunization commitments, and improving healthcare infrastructure across multiple countries. Rapid economic growth in China, India, and Southeast Asian nations has enabled increased domestic vaccine manufacturing capacity and public health investments. Significant birth cohorts create sustained demand for pediatric vaccines, while aging populations require expanded adult immunization programs against influenza, pneumococcal disease, and herpes zoster. Regional initiatives promoting indigenous vaccine production, including the Serum Institute of India's massive manufacturing scale, reduce import dependence and improve supply security. International organization partnerships supporting immunization expansion in lower-income Asia Pacific countries further accelerate regional market growth.
Key players in the market
Some of the key players in Vaccine Market include Pfizer Inc, Moderna Inc, Johnson and Johnson, GlaxoSmithKline plc, Sanofi SA, Merck and Co Inc, AstraZeneca plc, Bharat Biotech International Limited, Serum Institute of India Pvt Ltd, Sinovac Biotech Ltd, Sinopharm Group Co Ltd, CSL Limited, Novavax Inc, BioNTech SE, Takeda Pharmaceutical Company Limited, and Emergent BioSolutions Inc.
Key Developments:
In April 2026, The European Commission approved ENFLONSIA (clesrovimab) for the prevention of RSV lower respiratory tract disease in infants during their first RSV season.
In March 2026, GSK’s Respiratory Syncytial Virus (RSV) vaccine, Arexvy, received FDA approval for an expanded age indication; covering adults aged 18–49 who are at increased risk of severe infection.
In December 2025, CSL officially opened its new $1 billion world-class vaccine and antivenom manufacturing facility in Melbourne, Australia, significantly boosting onshore cell-based influenza vaccine production.
Vaccine Types Covered:
- Live Attenuated Vaccines
- Inactivated Vaccines
- Subunit Vaccines
- Monovalent Vaccines
- Multivalent Vaccines
- Viral Diseases
- Bacterial Diseases
- Cancer Vaccines
- Allergy Vaccines
- Other Therapeutic Vaccines
- Parenteral
- Oral
- Intranasal
- Pediatric Vaccines
- Adult Vaccines
- In-House Manufacturing
- Contract Manufacturing Organizations (CMOs)
- Public Sector Manufacturing
- Standard Cold Chain Vaccines
- Ultra-Cold Chain Vaccines
- Thermostable Vaccines
- Hospitals
- Clinics
- Vaccination Centers
- Government Immunization Programs
- NGOs & International Organizations
- Government Supply Programs
- Institutional Supply
- Retail Pharmacies
- Other Channels
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
- Rest of the World (RoW)
- Middle East
- Saudi Arabia
- United Arab Emirates
- Qatar
- Israel
- Rest of Middle East
- Africa
- South Africa
- Egypt
- Morocco
- Rest of Africa
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
1 EXECUTIVE SUMMARY
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 RESEARCH FRAMEWORK
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 MARKET DYNAMICS AND TREND ANALYSIS
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 COMPETITIVE AND STRATEGIC ASSESSMENT
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 GLOBAL VACCINE MARKET, BY VACCINE TYPE
5.1 Live Attenuated Vaccines
5.2 Inactivated Vaccines
5.3 Subunit Vaccines
5.3.1 Recombinant Vaccines
5.3.2 Conjugate Vaccines
5.4 Toxoid Vaccines
5.5 mRNA Vaccines
5.6 Viral Vector Vaccines
5.7 DNA Vaccines
5.8 Combination Vaccines
6 GLOBAL VACCINE MARKET, BY VALENCY TYPE
6.1 Monovalent Vaccines
6.2 Multivalent Vaccines
7 GLOBAL VACCINE MARKET, BY DISEASE INDICATION
7.1 Viral Diseases
7.1.1 Influenza
7.1.2 COVID-19
7.1.3 Hepatitis
7.1.4 HPV
7.1.5 Measles, Mumps, Rubella (MMR)
7.1.6 Rotavirus
7.1.7 Varicella
7.1.8 Respiratory Syncytial Virus (RSV)
7.1.9 Other Viral Diseases
7.2 Bacterial Diseases
7.2.1 Pneumococcal Diseases
7.2.2 Meningococcal Diseases
7.2.3 DTP (Diphtheria, Tetanus, Pertussis)
7.2.4 Tuberculosis (BCG)
7.2.5 Other Bacterial Diseases
7.3 Cancer Vaccines
7.4 Allergy Vaccines
7.5 Other Therapeutic Vaccines
8 GLOBAL VACCINE MARKET, BY ROUTE OF ADMINISTRATION
8.1 Parenteral
8.2 Oral
8.3 Intranasal
9 GLOBAL VACCINE MARKET, BY AGE GROUP
9.1 Pediatric Vaccines
9.2 Adult Vaccines
10 GLOBAL VACCINE MARKET, BY MANUFACTURING MODEL
10.1 In-House Manufacturing
10.2 Contract Manufacturing Organizations (CMOs)
10.3 Public Sector Manufacturing
11 GLOBAL VACCINE MARKET, BY STORAGE & LOGISTICS
11.1 Standard Cold Chain Vaccines
11.2 Ultra-Cold Chain Vaccines
11.3 Thermostable Vaccines
12 GLOBAL VACCINE MARKET, BY END USER
12.1 Hospitals
12.2 Clinics
12.3 Vaccination Centers
12.4 Government Immunization Programs
12.5 NGOs & International Organizations
13 GLOBAL VACCINE MARKET, BY DISTRIBUTION CHANNEL
13.1 Government Supply Programs
13.2 Institutional Supply
13.3 Retail Pharmacies
13.4 Other Channels
14 GLOBAL VACCINE MARKET, BY GEOGRAPHY
14.1 North America
14.1.1 United States
14.1.2 Canada
14.1.3 Mexico
14.2 Europe
14.2.1 United Kingdom
14.2.2 Germany
14.2.3 France
14.2.4 Italy
14.2.5 Spain
14.2.6 Netherlands
14.2.7 Belgium
14.2.8 Sweden
14.2.9 Switzerland
14.2.10 Poland
14.2.11 Rest of Europe
14.3 Asia Pacific
14.3.1 China
14.3.2 Japan
14.3.3 India
14.3.4 South Korea
14.3.5 Australia
14.3.6 Indonesia
14.3.7 Thailand
14.3.8 Malaysia
14.3.9 Singapore
14.3.10 Vietnam
14.3.11 Rest of Asia Pacific
14.4 South America
14.4.1 Brazil
14.4.2 Argentina
14.4.3 Colombia
14.4.4 Chile
14.4.5 Peru
14.4.6 Rest of South America
14.5 Rest of the World (RoW)
14.5.1 Middle East
14.5.1.1 Saudi Arabia
14.5.1.2 United Arab Emirates
14.5.1.3 Qatar
14.5.1.4 Israel
14.5.1.5 Rest of Middle East
14.5.2 Africa
14.5.2.1 South Africa
14.5.2.2 Egypt
14.5.2.3 Morocco
14.5.2.4 Rest of Africa
15 STRATEGIC MARKET INTELLIGENCE
15.1 Industry Value Network and Supply Chain Assessment
15.2 White-Space and Opportunity Mapping
15.3 Product Evolution and Market Life Cycle Analysis
15.4 Channel, Distributor, and Go-to-Market Assessment
16 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES
16.1 Mergers and Acquisitions
16.2 Partnerships, Alliances, and Joint Ventures
16.3 New Product Launches and Certifications
16.4 Capacity Expansion and Investments
16.5 Other Strategic Initiatives
17 COMPANY PROFILES
17.1 Pfizer Inc
17.2 Moderna Inc
17.3 Johnson and Johnson
17.4 GlaxoSmithKline plc
17.5 Sanofi SA
17.6 Merck and Co Inc
17.7 AstraZeneca plc
17.8 Bharat Biotech International Limited
17.9 Serum Institute of India Pvt Ltd
17.10 Sinovac Biotech Ltd
17.11 Sinopharm Group Co Ltd
17.12 CSL Limited
17.13 Novavax Inc
17.14 BioNTech SE
17.15 Takeda Pharmaceutical Company Limited
17.16 Emergent BioSolutions Inc
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 RESEARCH FRAMEWORK
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 MARKET DYNAMICS AND TREND ANALYSIS
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 COMPETITIVE AND STRATEGIC ASSESSMENT
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 GLOBAL VACCINE MARKET, BY VACCINE TYPE
5.1 Live Attenuated Vaccines
5.2 Inactivated Vaccines
5.3 Subunit Vaccines
5.3.1 Recombinant Vaccines
5.3.2 Conjugate Vaccines
5.4 Toxoid Vaccines
5.5 mRNA Vaccines
5.6 Viral Vector Vaccines
5.7 DNA Vaccines
5.8 Combination Vaccines
6 GLOBAL VACCINE MARKET, BY VALENCY TYPE
6.1 Monovalent Vaccines
6.2 Multivalent Vaccines
7 GLOBAL VACCINE MARKET, BY DISEASE INDICATION
7.1 Viral Diseases
7.1.1 Influenza
7.1.2 COVID-19
7.1.3 Hepatitis
7.1.4 HPV
7.1.5 Measles, Mumps, Rubella (MMR)
7.1.6 Rotavirus
7.1.7 Varicella
7.1.8 Respiratory Syncytial Virus (RSV)
7.1.9 Other Viral Diseases
7.2 Bacterial Diseases
7.2.1 Pneumococcal Diseases
7.2.2 Meningococcal Diseases
7.2.3 DTP (Diphtheria, Tetanus, Pertussis)
7.2.4 Tuberculosis (BCG)
7.2.5 Other Bacterial Diseases
7.3 Cancer Vaccines
7.4 Allergy Vaccines
7.5 Other Therapeutic Vaccines
8 GLOBAL VACCINE MARKET, BY ROUTE OF ADMINISTRATION
8.1 Parenteral
8.2 Oral
8.3 Intranasal
9 GLOBAL VACCINE MARKET, BY AGE GROUP
9.1 Pediatric Vaccines
9.2 Adult Vaccines
10 GLOBAL VACCINE MARKET, BY MANUFACTURING MODEL
10.1 In-House Manufacturing
10.2 Contract Manufacturing Organizations (CMOs)
10.3 Public Sector Manufacturing
11 GLOBAL VACCINE MARKET, BY STORAGE & LOGISTICS
11.1 Standard Cold Chain Vaccines
11.2 Ultra-Cold Chain Vaccines
11.3 Thermostable Vaccines
12 GLOBAL VACCINE MARKET, BY END USER
12.1 Hospitals
12.2 Clinics
12.3 Vaccination Centers
12.4 Government Immunization Programs
12.5 NGOs & International Organizations
13 GLOBAL VACCINE MARKET, BY DISTRIBUTION CHANNEL
13.1 Government Supply Programs
13.2 Institutional Supply
13.3 Retail Pharmacies
13.4 Other Channels
14 GLOBAL VACCINE MARKET, BY GEOGRAPHY
14.1 North America
14.1.1 United States
14.1.2 Canada
14.1.3 Mexico
14.2 Europe
14.2.1 United Kingdom
14.2.2 Germany
14.2.3 France
14.2.4 Italy
14.2.5 Spain
14.2.6 Netherlands
14.2.7 Belgium
14.2.8 Sweden
14.2.9 Switzerland
14.2.10 Poland
14.2.11 Rest of Europe
14.3 Asia Pacific
14.3.1 China
14.3.2 Japan
14.3.3 India
14.3.4 South Korea
14.3.5 Australia
14.3.6 Indonesia
14.3.7 Thailand
14.3.8 Malaysia
14.3.9 Singapore
14.3.10 Vietnam
14.3.11 Rest of Asia Pacific
14.4 South America
14.4.1 Brazil
14.4.2 Argentina
14.4.3 Colombia
14.4.4 Chile
14.4.5 Peru
14.4.6 Rest of South America
14.5 Rest of the World (RoW)
14.5.1 Middle East
14.5.1.1 Saudi Arabia
14.5.1.2 United Arab Emirates
14.5.1.3 Qatar
14.5.1.4 Israel
14.5.1.5 Rest of Middle East
14.5.2 Africa
14.5.2.1 South Africa
14.5.2.2 Egypt
14.5.2.3 Morocco
14.5.2.4 Rest of Africa
15 STRATEGIC MARKET INTELLIGENCE
15.1 Industry Value Network and Supply Chain Assessment
15.2 White-Space and Opportunity Mapping
15.3 Product Evolution and Market Life Cycle Analysis
15.4 Channel, Distributor, and Go-to-Market Assessment
16 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES
16.1 Mergers and Acquisitions
16.2 Partnerships, Alliances, and Joint Ventures
16.3 New Product Launches and Certifications
16.4 Capacity Expansion and Investments
16.5 Other Strategic Initiatives
17 COMPANY PROFILES
17.1 Pfizer Inc
17.2 Moderna Inc
17.3 Johnson and Johnson
17.4 GlaxoSmithKline plc
17.5 Sanofi SA
17.6 Merck and Co Inc
17.7 AstraZeneca plc
17.8 Bharat Biotech International Limited
17.9 Serum Institute of India Pvt Ltd
17.10 Sinovac Biotech Ltd
17.11 Sinopharm Group Co Ltd
17.12 CSL Limited
17.13 Novavax Inc
17.14 BioNTech SE
17.15 Takeda Pharmaceutical Company Limited
17.16 Emergent BioSolutions Inc
LIST OF TABLES
Table 1 Global Vaccine Market Outlook, By Region (2023–2034) ($MN)
Table 2 Global Vaccine Market Outlook, By Vaccine Type (2023–2034) ($MN)
Table 3 Global Vaccine Market Outlook, By Live Attenuated Vaccines (2023–2034) ($MN)
Table 4 Global Vaccine Market Outlook, By Inactivated Vaccines (2023–2034) ($MN)
Table 5 Global Vaccine Market Outlook, By Subunit Vaccines (2023–2034) ($MN)
Table 6 Global Vaccine Market Outlook, By Recombinant Vaccines (2023–2034) ($MN)
Table 7 Global Vaccine Market Outlook, By Conjugate Vaccines (2023–2034) ($MN)
Table 8 Global Vaccine Market Outlook, By Toxoid Vaccines (2023–2034) ($MN)
Table 9 Global Vaccine Market Outlook, By mRNA Vaccines (2023–2034) ($MN)
Table 10 Global Vaccine Market Outlook, By Viral Vector Vaccines (2023–2034) ($MN)
Table 11 Global Vaccine Market Outlook, By DNA Vaccines (2023–2034) ($MN)
Table 12 Global Vaccine Market Outlook, By Combination Vaccines (2023–2034) ($MN)
Table 13 Global Vaccine Market Outlook, By Valency Type (2023–2034) ($MN)
Table 14 Global Vaccine Market Outlook, By Monovalent Vaccines (2023–2034) ($MN)
Table 15 Global Vaccine Market Outlook, By Multivalent Vaccines (2023–2034) ($MN)
Table 16 Global Vaccine Market Outlook, By Disease Indication (2023–2034) ($MN)
Table 17 Global Vaccine Market Outlook, By Viral Diseases (2023–2034) ($MN)
Table 18 Global Vaccine Market Outlook, By Influenza (2023–2034) ($MN)
Table 19 Global Vaccine Market Outlook, By COVID-19 (2023–2034) ($MN)
Table 20 Global Vaccine Market Outlook, By Hepatitis (2023–2034) ($MN)
Table 21 Global Vaccine Market Outlook, By HPV (2023–2034) ($MN)
Table 22 Global Vaccine Market Outlook, By Measles, Mumps, Rubella (MMR) (2023–2034) ($MN)
Table 23 Global Vaccine Market Outlook, By Rotavirus (2023–2034) ($MN)
Table 24 Global Vaccine Market Outlook, By Varicella (2023–2034) ($MN)
Table 25 Global Vaccine Market Outlook, By Respiratory Syncytial Virus (RSV) (2023–2034) ($MN)
Table 26 Global Vaccine Market Outlook, By Other Viral Diseases (2023–2034) ($MN)
Table 27 Global Vaccine Market Outlook, By Bacterial Diseases (2023–2034) ($MN)
Table 28 Global Vaccine Market Outlook, By Pneumococcal Diseases (2023–2034) ($MN)
Table 29 Global Vaccine Market Outlook, By Meningococcal Diseases (2023–2034) ($MN)
Table 30 Global Vaccine Market Outlook, By DTP (Diphtheria, Tetanus, Pertussis) (2023–2034) ($MN)
Table 31 Global Vaccine Market Outlook, By Tuberculosis (BCG) (2023–2034) ($MN)
Table 32 Global Vaccine Market Outlook, By Other Bacterial Diseases (2023–2034) ($MN)
Table 33 Global Vaccine Market Outlook, By Cancer Vaccines (2023–2034) ($MN)
Table 34 Global Vaccine Market Outlook, By Allergy Vaccines (2023–2034) ($MN)
Table 35 Global Vaccine Market Outlook, By Other Therapeutic Vaccines (2023–2034) ($MN)
Table 36 Global Vaccine Market Outlook, By Route of Administration (2023–2034) ($MN)
Table 37 Global Vaccine Market Outlook, By Parenteral (2023–2034) ($MN)
Table 38 Global Vaccine Market Outlook, By Oral (2023–2034) ($MN)
Table 39 Global Vaccine Market Outlook, By Intranasal (2023–2034) ($MN)
Table 40 Global Vaccine Market Outlook, By Age Group (2023–2034) ($MN)
Table 41 Global Vaccine Market Outlook, By Pediatric Vaccines (2023–2034) ($MN)
Table 42 Global Vaccine Market Outlook, By Adult Vaccines (2023–2034) ($MN)
Table 43 Global Vaccine Market Outlook, By Manufacturing Model (2023–2034) ($MN)
Table 44 Global Vaccine Market Outlook, By In-House Manufacturing (2023–2034) ($MN)
Table 45 Global Vaccine Market Outlook, By Contract Manufacturing Organizations (CMOs) (2023–2034) ($MN)
Table 46 Global Vaccine Market Outlook, By Public Sector Manufacturing (2023–2034) ($MN)
Table 47 Global Vaccine Market Outlook, By Storage & Logistics (2023–2034) ($MN)
Table 48 Global Vaccine Market Outlook, By Standard Cold Chain Vaccines (2023–2034) ($MN)
Table 49 Global Vaccine Market Outlook, By Ultra-Cold Chain Vaccines (2023–2034) ($MN)
Table 50 Global Vaccine Market Outlook, By Thermostable Vaccines (2023–2034) ($MN)
Table 51 Global Vaccine Market Outlook, By End User (2023–2034) ($MN)
Table 52 Global Vaccine Market Outlook, By Hospitals (2023–2034) ($MN)
Table 53 Global Vaccine Market Outlook, By Clinics (2023–2034) ($MN)
Table 54 Global Vaccine Market Outlook, By Vaccination Centers (2023–2034) ($MN)
Table 55 Global Vaccine Market Outlook, By Government Immunization Programs (2023–2034) ($MN)
Table 56 Global Vaccine Market Outlook, By NGOs & International Organizations (2023–2034) ($MN)
Table 57 Global Vaccine Market Outlook, By Distribution Channel (2023–2034) ($MN)
Table 58 Global Vaccine Market Outlook, By Government Supply Programs (2023–2034) ($MN)
Table 59 Global Vaccine Market Outlook, By Institutional Supply (2023–2034) ($MN)
Table 60 Global Vaccine Market Outlook, By Retail Pharmacies (2023–2034) ($MN)
Table 61 Global Vaccine Market Outlook, By Other Channels (2023–2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.
Table 1 Global Vaccine Market Outlook, By Region (2023–2034) ($MN)
Table 2 Global Vaccine Market Outlook, By Vaccine Type (2023–2034) ($MN)
Table 3 Global Vaccine Market Outlook, By Live Attenuated Vaccines (2023–2034) ($MN)
Table 4 Global Vaccine Market Outlook, By Inactivated Vaccines (2023–2034) ($MN)
Table 5 Global Vaccine Market Outlook, By Subunit Vaccines (2023–2034) ($MN)
Table 6 Global Vaccine Market Outlook, By Recombinant Vaccines (2023–2034) ($MN)
Table 7 Global Vaccine Market Outlook, By Conjugate Vaccines (2023–2034) ($MN)
Table 8 Global Vaccine Market Outlook, By Toxoid Vaccines (2023–2034) ($MN)
Table 9 Global Vaccine Market Outlook, By mRNA Vaccines (2023–2034) ($MN)
Table 10 Global Vaccine Market Outlook, By Viral Vector Vaccines (2023–2034) ($MN)
Table 11 Global Vaccine Market Outlook, By DNA Vaccines (2023–2034) ($MN)
Table 12 Global Vaccine Market Outlook, By Combination Vaccines (2023–2034) ($MN)
Table 13 Global Vaccine Market Outlook, By Valency Type (2023–2034) ($MN)
Table 14 Global Vaccine Market Outlook, By Monovalent Vaccines (2023–2034) ($MN)
Table 15 Global Vaccine Market Outlook, By Multivalent Vaccines (2023–2034) ($MN)
Table 16 Global Vaccine Market Outlook, By Disease Indication (2023–2034) ($MN)
Table 17 Global Vaccine Market Outlook, By Viral Diseases (2023–2034) ($MN)
Table 18 Global Vaccine Market Outlook, By Influenza (2023–2034) ($MN)
Table 19 Global Vaccine Market Outlook, By COVID-19 (2023–2034) ($MN)
Table 20 Global Vaccine Market Outlook, By Hepatitis (2023–2034) ($MN)
Table 21 Global Vaccine Market Outlook, By HPV (2023–2034) ($MN)
Table 22 Global Vaccine Market Outlook, By Measles, Mumps, Rubella (MMR) (2023–2034) ($MN)
Table 23 Global Vaccine Market Outlook, By Rotavirus (2023–2034) ($MN)
Table 24 Global Vaccine Market Outlook, By Varicella (2023–2034) ($MN)
Table 25 Global Vaccine Market Outlook, By Respiratory Syncytial Virus (RSV) (2023–2034) ($MN)
Table 26 Global Vaccine Market Outlook, By Other Viral Diseases (2023–2034) ($MN)
Table 27 Global Vaccine Market Outlook, By Bacterial Diseases (2023–2034) ($MN)
Table 28 Global Vaccine Market Outlook, By Pneumococcal Diseases (2023–2034) ($MN)
Table 29 Global Vaccine Market Outlook, By Meningococcal Diseases (2023–2034) ($MN)
Table 30 Global Vaccine Market Outlook, By DTP (Diphtheria, Tetanus, Pertussis) (2023–2034) ($MN)
Table 31 Global Vaccine Market Outlook, By Tuberculosis (BCG) (2023–2034) ($MN)
Table 32 Global Vaccine Market Outlook, By Other Bacterial Diseases (2023–2034) ($MN)
Table 33 Global Vaccine Market Outlook, By Cancer Vaccines (2023–2034) ($MN)
Table 34 Global Vaccine Market Outlook, By Allergy Vaccines (2023–2034) ($MN)
Table 35 Global Vaccine Market Outlook, By Other Therapeutic Vaccines (2023–2034) ($MN)
Table 36 Global Vaccine Market Outlook, By Route of Administration (2023–2034) ($MN)
Table 37 Global Vaccine Market Outlook, By Parenteral (2023–2034) ($MN)
Table 38 Global Vaccine Market Outlook, By Oral (2023–2034) ($MN)
Table 39 Global Vaccine Market Outlook, By Intranasal (2023–2034) ($MN)
Table 40 Global Vaccine Market Outlook, By Age Group (2023–2034) ($MN)
Table 41 Global Vaccine Market Outlook, By Pediatric Vaccines (2023–2034) ($MN)
Table 42 Global Vaccine Market Outlook, By Adult Vaccines (2023–2034) ($MN)
Table 43 Global Vaccine Market Outlook, By Manufacturing Model (2023–2034) ($MN)
Table 44 Global Vaccine Market Outlook, By In-House Manufacturing (2023–2034) ($MN)
Table 45 Global Vaccine Market Outlook, By Contract Manufacturing Organizations (CMOs) (2023–2034) ($MN)
Table 46 Global Vaccine Market Outlook, By Public Sector Manufacturing (2023–2034) ($MN)
Table 47 Global Vaccine Market Outlook, By Storage & Logistics (2023–2034) ($MN)
Table 48 Global Vaccine Market Outlook, By Standard Cold Chain Vaccines (2023–2034) ($MN)
Table 49 Global Vaccine Market Outlook, By Ultra-Cold Chain Vaccines (2023–2034) ($MN)
Table 50 Global Vaccine Market Outlook, By Thermostable Vaccines (2023–2034) ($MN)
Table 51 Global Vaccine Market Outlook, By End User (2023–2034) ($MN)
Table 52 Global Vaccine Market Outlook, By Hospitals (2023–2034) ($MN)
Table 53 Global Vaccine Market Outlook, By Clinics (2023–2034) ($MN)
Table 54 Global Vaccine Market Outlook, By Vaccination Centers (2023–2034) ($MN)
Table 55 Global Vaccine Market Outlook, By Government Immunization Programs (2023–2034) ($MN)
Table 56 Global Vaccine Market Outlook, By NGOs & International Organizations (2023–2034) ($MN)
Table 57 Global Vaccine Market Outlook, By Distribution Channel (2023–2034) ($MN)
Table 58 Global Vaccine Market Outlook, By Government Supply Programs (2023–2034) ($MN)
Table 59 Global Vaccine Market Outlook, By Institutional Supply (2023–2034) ($MN)
Table 60 Global Vaccine Market Outlook, By Retail Pharmacies (2023–2034) ($MN)
Table 61 Global Vaccine Market Outlook, By Other Channels (2023–2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.
